HAVCR2 and esophageal squamous cell carcinoma: Through assessment of the diverse expression patterns of immune checkpoints, we noticed a significant enrichment of interactions, including TIGIT-PVR and LGALS9-HAVCR2 in baseline IPR tumors, suggesting novel immunotherapy targets for ESCC patients who may not benefit from NAT (Fig. 3J, K).